Facebook
X
LinkedIn
Forward
Precision Radiotherapy for Liver and Pancreatic Malignancies: Indications, Techniques and Response Evaluation
This activity focuses on the multidisciplinary care of liver and pancreatic cancer highlighting the role of radiation therapy. One talk discusses the role of radiation therapy in the hepatocellular carcinoma, focusing on evidence supporting the use of radiotherapy across multiple settings: definitive treatment in early stage, combination therapy in advanced disease, bridge or downstaging to transplant and for palliation. Radiation oncologists sometimes do not fully engage in the multidisciplinary discussion of these patients with complex and challenging malignancies due to unfamiliarity with the indications for radiation therapy, the integration of RT in the multidisciplinary care and/or due to lack of familiarity in planning and delivery of moving and changing target volumes and organ at risk. One of the talks discusses promising data on the emerging role of dose escalated radiation therapy in the definitive management of locally advanced pancreatic cancer, the use of elective volumes for pancreas SBRT, and also provides learners practical advice on how this can be safely delivered. The third talk discusses the complex imaging changes that occur in the liver after SBRT or hypofractionated radiotherapy. Radiation oncologists must have this knowledge to discuss with their radiology colleagues to appropriately differentiate what are expected post treatment changes and what may be signs of progression. This activity addresses these challenges.
Topics:
- Ablative Radiation Therapy for Locally Advanced Pancreatic Cancer: Clinical Indications and Practical Considerations
Michael David Chuong, MD - Integrating Radiotherapy into Multidisciplinary Care for Hepatocellular Carcinoma
Nina N. Sanford, MD - Post-Radiotherapy Imaging Response Assessment in Hepatobiliary Cancers
Smith "Jim" Apisarnthanarax, MD - Q and A
Najeeb Mohideen, MD, FASTRO - Moderator
Full Panel
This activity is available from July 14, 2026, through 11:59 p.m. Eastern time on July 13, 2028.
The content was originally presented and recorded at the 2025 ASTRO Annual Meeting.
Target Audience
The activity is designed to meet the interests of radiation oncologists, physicists, diagnostic radiologists, radiation biologists, residents and specialists in radiology, IR, HPB surgery, transplant surgery, hepatology and medical oncology.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Understand practical considerations for safely treating and escalating radiation dose to tumors in the upper abdomen.
- Increase awareness of trials of radiation therapy in liver and pancreatic cancer.
- Share practical tips for patient selection, treatment and response evaluation for radiotherapy.
Moderator:
- Najeeb Mohideen, MD, FASTRO, is employed by Northwest Community Hospital. Dr. Mohideen has no relevant financial relationship with ineligible companies to disclose.
Speakers:
- Michael David Chuong, MD, is employed by Miami Cancer Institute, Baptist Health South Florida. Dr. Chuong receives grant/research funding from Novocure.
- Nina N. Sanford, MD, is employed by UT Southwestern Medical Center. Dr. Sanford has no relevant financial relationship with ineligible companies to disclose.
- Smith Apisarnthanarax, MD, is employed by University of Washington. Dr. Apisarnthanarax has no relevant financial relationship with ineligible companies to disclose.
Planners:
- Malcolm Mattes, MD, is employed at Rutgers Cancer Institute. Dr. Mattes received research/grant funding from Gilead Sciences (relationship ended 8/30/2025). Dr. Mattes has no relevant financial relationship with ineligible companies.
- Parul Barry, MD, is employed by the University of Pittsburgh Medical Center. Dr. Barry has no relevant financial relationship with ineligible companies.
- Michael Haddock, MD, is employed by Mayo Clinic and has no relevant financial relationship with ineligible companies to disclose.
- Manisha Palta, MD, is employed by Duke Cancer Center and Duke University Hospital. Dr. Palta receives grant/research funding from Merck and Varian Medical Systems.
- Salma Jabbour, MD, is employed by Rutgers Cancer Institute. Dr. Jabbour receives grant/research funding from Merck & Co., Inc. and Beigene. Dr. Jabbour receives compensation/payment as a consultant with Radialogica and IMX Medical.
All relevant financial relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 1.25 AMA PRA Category 1 Credit™
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
Price
Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.
- Nonmember: $149
- Member: $99
- Member-in-Training: $49
- Student/Graduate Student/PGY-1 Member: $49
- Postdoctoral Fellow Member: $49
If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.
Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date.
Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.
The activity and its materials will only be available on the ASTRO website until July 13, 2028, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.